Jaya Kumar, MD
Ophthalmology · Orlando, FLNPI 1871855049
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.6%), food and beverage and other — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by AbbVie at 35.6% of the total. Reporting peaked in 2019 at $10,797 and has fallen 93.3% since, to $727 in 2025. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 210 payments — averaging $93.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$7K
- Novartis$4K
- US Retina LLC$2K
- Alimera Sciences, Inc.$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Genentech USA, Inc.$1K
- plus $2K from 12 others
Across 11 payments — averaging $461.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$5K
- Notal Vision, Inc.$120
What the payments were for
- Consulting fees$9,93351%
- Speaking & faculty fees$1,2006%
- Travel & lodging$640%
- Food & beverage$6,01231%
- Ownership interest$7584%
- Other$1,6638%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 41 | $6,986 |
| Novartis | 12 | $4,392 |
| US Retina LLC | 4 | $2,421 |
| Alimera Sciences, Inc. | 27 | $2,049 |
| Regeneron Healthcare Solutions, Inc. | 40 | $1,270 |
| Genentech USA, Inc. | 32 | $1,004 |
| Apellis Pharmaceuticals, Inc. | 16 | $462 |
| Notal Vision, Inc. | 12 | $338 |
| Astellas Pharma US Inc | 6 | $160 |
| ANI Pharmaceuticals, Inc. | 5 | $115 |
| Regeneron | 1 | $113 |
| Mallinckrodt Hospital Products Inc. | 5 | $101 |
| Coherus Oncology, Inc. | 2 | $73 |
| Harrow Eye, LLC | 2 | $53 |
| Sandoz | 1 | $36 |
| Eyepoint US, Inc. | 2 | $29 |
| Alcon | 1 | $19 |
| Oculus Surgical Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,630 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EyleaAflibercept | 49 | $140,807 |
| SyfovrePegcetacoplan/Pf | 34 | $105,120 |
| VabysmoFaricimab-Svoa | 20 | $66,226 |
| Prednisolone Acetate | 255 | $6,956 |
| LumiganBimatoprost | 12 | $3,967 |
| Bromfenac Sodium | 24 | $3,569 |
| CombiganBrimonidine Tartrate/Timolol | 16 | $3,094 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 175 | $2,219 |
| Ketorolac Tromethamine | 69 | $1,941 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 110 | $1,403 |
| Latanoprost | 131 | $1,368 |
| Atropine Sulfate | 51 | $1,283 |
| Brimonidine Tartrate | 106 | $1,115 |
| Timolol Maleate | 82 | $655 |
| Dorzolamide Hcl | 12 | $245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Regeneron Healthcare Solutions, Inc.Eylea | $1,270 | $140,80749 claims |
| Apellis Pharmaceuticals, Inc.Syfovre | $462 | $105,12034 claims |
| Genentech USA, Inc.Vabysmo | $1,004 | $66,22620 claims |
| AbbVieLumigan, Combigan | $6,986 | $7,06028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Orlando
- Matthew CunninghamOrlando$400K
- Sarina AminOrlando$138K
- Samuel Houston IiiOrlando$132K
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.